PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Pfizer, MedImmune, Roche, and Bristol-Myers Squibb intended to find methods to enable prediction and prevention of PML associated with immunomodulatory and immunosuppressive treatments.
"T Cell Deficiencies as a Common Risk Factor for Drug Associated Progressive Multifocal Leukoencephalopathy", written by the Consortium’s Clinical Working Group, has been published in Immunobiology. Read it now.
Review Article Published “Progressive Multifocal Leukoencephalopathy: Current Treatment Options and Future Perspectives,” authored by members of the PML Consortium Clinical and Research Working Groups, has been published in Therapeutic Advances in Neurological Disorders. Access the full article via PubMed.
